Brief: Paxmedica Enters Research Collaboration Agreement With Polomar Health
08/06/2023 15:33
June 8 (Reuters) - PaxMedica Inc PXMD.O :
* PAXMEDICA ENTERS RESEARCH COLLABORATION AGREEMENT WITH
POLOMAR
HEALTH FOR PHASE II STUDY IN AUTISM SPECTRUM DISORDER
* PAXMEDICA INC - UNDER AGREEMENT, POLOMAR HEALTH WILL
RETAIN
RIGHTS TO DEVELOP AND COMMERCIALIZE ANY NON-PRESCRIPTION
SUPPLEMENT FORM OF PRODUCT
* PAXMEDICA INC - PHASE II PROOF-OF-CONCEPT TRIAL, IS
ANTICIPATED
TO BEGIN IN Q2 OF 2023
Source text for Eikon: ID:nGNXbTYGMv
Further company coverage: PXMD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kuvatris Therapeutics
See all newsBrief: PaxMedica Responds To Emergency Request For IV Suramin And Commits To Provide Immediate Access To PAX-101
PaxMedica rises on Malawi's request for access to sleeping sickness drug
Brief: Paxmedica Receives Emergency Request For Iv Suramin From African Health Ministry For Use In Treating Fatal Sleeping Sickness
Brief: PaxMedica Achieves Key Milestone In The Development Of PAX-101 And Provides Update On Potential NDA Submission
Brief: Paxmedica Announces Pricing Of $7.0 Million Public Offering